No connection

Search Results

AHCO vs IMTX

AHCO
AdaptHealth Corp.
BEARISH
Price
$10.60
Market Cap
$1.44B
Sector
Healthcare
AI Confidence
85%
IMTX
Immatics N.V.
BEARISH
Price
$10.43
Market Cap
$1.4B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AHCO
--
IMTX
--
Forward P/E
AHCO
8.52
IMTX
-5.91
P/B Ratio
AHCO
0.92
IMTX
2.5
P/S Ratio
AHCO
0.44
IMTX
28.98
EV/EBITDA
AHCO
5.53
IMTX
-5.47

Profitability

Gross Margin
AHCO
20.89%
IMTX
-280.87%
Operating Margin
AHCO
6.2%
IMTX
-196.76%
Profit Margin
AHCO
-2.18%
IMTX
0.0%
ROE
AHCO
-4.25%
IMTX
-37.1%
ROA
AHCO
2.9%
IMTX
-18.08%

Growth

Revenue Growth
AHCO
-1.2%
IMTX
-64.9%
Earnings Growth
AHCO
--
IMTX
--

Financial Health

Debt/Equity
AHCO
1.25
IMTX
0.03
Current Ratio
AHCO
1.02
IMTX
11.72
Quick Ratio
AHCO
0.71
IMTX
11.07

Dividends

Dividend Yield
AHCO
--
IMTX
--
Payout Ratio
AHCO
0.0%
IMTX
0.0%

AI Verdict

AHCO BEARISH

AHCO's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, with negative ROE (-4.25%) and declining revenue (-1.20% YoY). The absence of an Altman Z-Score raises concern about bankruptcy risk, while the Graham Number and intrinsic value are unavailable, suggesting no reliable fundamental valuation anchor. Despite a modest 1Y return of +10.2%, the stock has underperformed over 3Y (-20.2%) and 5Y (-72.3%), reflecting deep structural issues. Analysts recommend 'buy' with a target of $12.88, but this optimism is not supported by deteriorating fundamentals or consistent earnings beats.

Strengths
Positive operating margin (6.20%) indicates some operational efficiency despite losses
Price/Sales of 0.44 suggests potential undervaluation relative to revenue
Recent Q/Q EPS growth of +68.8% shows possible short-term recovery momentum
Risks
Piotroski F-Score of 2/9 signals severe financial weakness and poor profitability trends
Negative profit margin (-2.18%) and declining revenue (-1.20% YoY) indicate deteriorating business fundamentals
Debt/Equity ratio of 1.25 is elevated, especially with a current ratio of 1.02 and quick ratio of 0.71, indicating liquidity strain
IMTX BEARISH

IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.

Strengths
Exceptional short-term liquidity with a Current Ratio of 11.72
Very low leverage with a Debt/Equity ratio of 0.03
Significant analyst price target upside (Target: $18.75 vs Price: $10.43)
Risks
Severe revenue contraction (-64.90% YoY)
Extreme operational inefficiency with Gross Margins at -280.87%
Critical Piotroski F-Score (1/9) signaling fundamental decay

Compare Another Pair

AHCO vs IMTX: Head-to-Head Comparison

This page compares AdaptHealth Corp. (AHCO) and Immatics N.V. (IMTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile